Predicting SPT-07A Pharmacokinetics in Rats, Dogs, and Humans
Author Information
Author(s): Zhu Xiaoqiang, Kong Weimin, Wang Zehua, Liu Xiaodong, Liu Li
Primary Institution: China Pharmaceutical University
Hypothesis
Can a physiologically-based pharmacokinetic model accurately predict the pharmacokinetics of SPT-07A in different species?
Conclusion
The pharmacokinetics of SPT-07A were successfully simulated using the developed PBPK model.
Supporting Evidence
- SPT-07A is primarily metabolized by UDP-glucuronosyltransferase (UGTs) in the liver, kidney, and intestine.
- The PBPK model predictions were validated against observed pharmacokinetic data.
- SPT-07A showed significant interspecies differences in metabolic clearance.
- UGT-mediated metabolism was the main pathway for SPT-07A elimination.
- The model successfully predicted plasma concentrations within the 5th–95th percentiles of simulations.
- SPT-07A's pharmacokinetics were influenced by hepatic and renal metabolic velocities.
- High extraction ratios in the liver suggest significant first-pass metabolism.
- SPT-07A is not suitable for oral administration due to low bioavailability.
Takeaway
Researchers created a model to predict how a drug called SPT-07A behaves in rats, dogs, and humans, and found it worked well.
Methodology
The study used in vitro metabolism studies and a physiologically-based pharmacokinetic model to simulate drug behavior in different species.
Limitations
The study did not account for interspecies differences in metabolism and extrahepatic metabolism in detail.
Participant Demographics
36 healthy volunteers, evenly divided into three dose cohorts (10 mg, 20 mg, and 40 mg).
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website